Terms ending in 2042
Every in-force patent on Twist Bioscience Corporation's record whose computed term ends in 2042, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,202,905 | Methods and Compositions Relating to Adenosine Receptors In force · High confidence | Twist Bioscience Corporation | In force | High confidence | |
| US 12,258,406 | Antibodies That Bind CD3 Epsilon In force · High confidence | Twist Bioscience Corporation | In force | High confidence | |
| US 12,173,282 | Antibodies That Bind CD3 Epsilon In force · High confidence | Twist Bioscience Corporation | In force | High confidence | |
| US 12,201,857 | Methods and Compositions Relating to Covid Antibody Epitopes In force · High confidence | Twist Bioscience Corporation | In force | High confidence | |
| US 12,091,777 | Variant Nucleic Acid Libraries for CRTH2 In force · High confidence | Twist Bioscience Corporation | In force | High confidence | |
| US 12,134,656 | DICKKOPF-1 Variant Antibodies and Methods of Use In force · High confidence | Twist Bioscience Corporation | In force | High confidence | |
| US 12,570,750 | Antibodies That Bind Adenosine A2A Receptors and Methods of Use Thereof to Treat Cancer and Neurological Diseases In force · High confidence | Twist Bioscience Corporation | In force | High confidence | |
| US 12,391,762 | Methods and Compositions Relating to GLP1R Variants In force · High confidence | Twist Bioscience Corporation | In force | High confidence |
8 of 8 patents shown. Soonest term end first, then patent number.
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.